What is the Origin of Dasatinib Quercetin Protocol?

This protocol originates from the field of geroscience, specifically the research into senolytics, which are agents that target and eliminate senescent cells. The combination was identified through high-throughput screening for compounds that could synergistically destroy these harmful, non-dividing cells. The foundational work links the accumulation of senescent cells to multiple age-related pathologies, including metabolic and hormonal dysregulation.

What is the Mechanism of Dasatinib Quercetin Protocol?

Dasatinib, a prescription drug, primarily targets and inhibits the survival pathways in certain senescent cell types, including hematopoietic progenitor cells. Quercetin, a natural polyphenol, simultaneously targets other senescent cell populations, particularly endothelial cells and murine bone marrow stem cells, by inhibiting anti-apoptotic proteins like Bcl-2 and Bcl-xL. The synergistic action of D+Q ensures a broader clearance of senescent cells, reducing the overall senescent cell burden and the secretion of their pro-inflammatory senescence-associated secretory phenotype (SASP) factors.

Dasatinib Quercetin Protocol ∞ Area

Dasatinib Quercetin Protocol

Meaning

The Dasatinib Quercetin Protocol, often abbreviated as D+Q, is a specific regimen involving the administration of two distinct compounds, the tyrosine kinase inhibitor Dasatinib and the flavonoid Quercetin, as a senolytic intervention. This protocol is clinically investigated for its ability to selectively induce apoptosis, or programmed cell death, in senescent cells that accumulate with age. By clearing these dysfunctional cells, the protocol aims to mitigate the chronic, low-grade inflammation they propagate, thereby promoting tissue rejuvenation and longevity.